This further adds to the growing body of literature that shows that a lower NLR could be a peripheral biomarker for the prediction of irAEs and cancer outcomes amongst those treated with either class of ICI (PD-1/PD-L1 or CTLA-4). Here, PDCD1 is linked to cancer.